We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Quick reference materials for primary care on diagnosing and understanding culture results for urinary tract infections (UTI).
Public Health England (PHE) uses a number of surveillance systems to collect HIV data nationally.
One and 3- year unadjusted and case-mix adjusted ‘percentage of all cancers diagnosed at stages 1 and 2’ indicator nationally and at sub–Integrated Care Board (sub-ICB) level.
The surveillance and epidemiology of human immunodeficiency virus (HIV).
Community diagnostic centre (CDC) sites have already delivered over 7 million tests, checks and scans to patients across England.
Summarises incidence and mechanisms of NAI resistance in seasonal influenza viruses and availability of NAI susceptibility testing in UK.
Guidance for people who have been diagnosed with a mpox infection and who have been advised to self-isolate at home.
This study assesses TB under-reporting and delayed treatment registration in 9 counties in China
This review describes how accurate these rapid diagnostic tests are for diagnosing visceral leishmaniasis
Information on the waiting times of patients with suspected cancer and those subsequently diagnosed with cancer.
The epidemiology, symptoms, diagnosis and management of human T-cell lymphotropic virus types 1 and 2 (HTLV-1 and HTLV-2).
Historical and current epidemiology of Zika virus infections, including cases in UK travellers.
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (11 March 2024) approved the medicine quizartinib (Vanflyta) to be used alongside chemotherapy as first line treatment for adults who have acute myeloid leukaemia (AML).
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).